Becker's Healthcare January 17, 2024
Erica Carbajal

The FDA on Jan. 16 approved Casgevy to be used as a treatment for beta-thalassemia. The move comes just over a month after the nation’s first medicine based on CRISPR gene-editing technology was approved to treat patients with sickle cell disease.

Casgevy was approved to treat patients 12 and older with beta-thalassemia, an inherited blood disorder that affects the ability to produce hemoglobin. Patients with the condition often require frequent blood transfusions.

“Today’s approval is an important step in the advancement of an additional treatment option for individuals with beta-thalassemia, a debilitating disease that places individuals at risk of many serious health problems,” Nicole Verdun, MD, director of...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Deep learning uncovers gene targets and potential drugs to slow brain aging
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
Common Trends in GLP-1 Use Amid Increased Indications
Ensitrelvir Shows Promise Preventing COVID-19 Post Exposure
Gene Therapy Biotech MeiraGTx Strikes Deal Bringing Generative AI to Pivotal Parkinson’s Trial

Share This Article